# Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles

> **NCT06868017** · PHASE4 · NOT_YET_RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 208 (estimated)

## Conditions studied

- HER2 Positive Breast Cancer

## Interventions

- **DRUG:** Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses
- **DRUG:** Cohort B will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 6 doses

## Key facts

- **NCT ID:** NCT06868017
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2026-02-19
- **Final completion:** 2027-02-19
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06868017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06868017, "Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06868017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*